Evonik, Stanford University to develop polymer-based drug delivery system

10:51 AM, 11th June 2021
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). This polymer-based platform complements Evonik's existing portfolio of lipid-based drug delivery, including LNPs.

ESSEN, GERMANY: Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). This polymer-based platform complements Evonik’s existing portfolio of lipid-based drug delivery, including LNPs. Starting this month, Evonik and Stanford scientists begin a three-year sponsored research collaboration to develop the polymer-based drug delivery system, which Evonik will license and commercialize.

The new drug delivery technology of Evonik’s Health Care business accelerates the portfolio shift of the life science division Nutrition & Care towards system solutions. Characterized by high growth prospects and above average margin potential, Nutrition & Care aims to increase the share of system solutions it offers from 20 percent today, to more than 50 percent by 2030.

“We are proud to collaborate with Stanford University and combine our innovative power in advanced drug delivery. Through this project we look forward to enabling the next generation of mRNA-based medicine,” said Dr. Thomas Riermeier, head of Evonik’s Health Care business line.

The delivery of mRNA effectively and safely into the cell is one of the biggest challenges for expanding the use of mRNA therapeutics to promising fields such as cancer immunotherapy, protein replacement and gene editing. As a leading integrated development and manufacturing partner for advanced drug delivery, Evonik is well-positioned to address many of the pharma industry’s unmet needs. Today, Evonik’s accessible market for LNP-based delivery systems alone is estimated to be in excess of $5 billion by 2026.

“If we are to harness the full potential of mRNA therapeutics, we will need a toolbox of drug delivery technologies to target an expanded range of tissues and organs. Therefore, it is a great pleasure to collaborate with Stanford University and bring our expertise in advanced drug delivery to commercialize the new platform,” said Dr. Stefan Randl, vice president of research, development & innovation for Evonik Health Care.

Evonik will work together with Stanford University scientists to scale up the synthesis and formulation, and further develop this innovative technology for organ selective delivery based on a non-animal-derived, synthetic degradable polymer. As one of the few integrated development and manufacturing partners for gene therapies, Evonik aims to make this technology available in GMP quality (Good Manufacturing Practice) for use in clinical-stage developments and ultimately on a commercial scale.

The new polymer-based delivery platform, known as Charge Altering Releasable Transporters (CART) was developed by professor Robert Waymouth, professor Paul Wender and professor Ronald Levy of Stanford University.

Across the entire pharmaceutical value chain, Evonik assumes a leading position as development and manufacturing partner. This includes pharmaceutical excipients such as lipids and custom lipids, formulation development and the manufacturing of clinical samples, as well as commercial drug products. The new polymer-based delivery system developed at Stanford University complements Evonik’s technology platform for mRNA delivery.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Kuraray to sell subsidiary Calgon's ultraviolet technologies business

TOKYO, JAPAN: Kuraray Co Ltd announced its decision to divest operations related to UV-based water treatment and ballast water treatment run by Calgon ...

Read more
bp pulse opens first fleet rapid charging hubs in UK

LONDON, UK: bp pulse said it has opened UK’s first rapid charging hub for fleet vehicles. The new multi-charger hub on Park Lane in Central Lond ...

Read more
PPG completes Nordic paint company Tikkurila's acquisition

PITTSBURGH, US: PPG announced that it has completed its acquisition of all of the shares of Tikkurila tendered into PPG’s tender offer as of the ...

Read more
Eastman, One Rock agree for rubber additives business sale

KINGSPORT, US: Eastman Chemical Company announced it has entered into a definitive agreement with an affiliate of One Rock Capital Partners LLC to sel ...

Read more
Evonik extends chairman Christian Kullmann's contract for five years

ESSEN, GERMANY: Christian Kullmann, who has been chairman of Evonik's executive board since May 2017, will head the Essen-based specialty chemicals co ...

Read more
Equinor agrees for Denmark-refining business sale to Klesch Group

STAVANGER, NORWAY: Equinor said it has entered into an agreement with the Klesch Group for the sale of its refining business in Denmark. Further comme ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X